CADE probes drugmaker for price hike

Brazil’s public prosecutor has complained against Gilead Sciences to the country’s competition enforcer, reportedly about the drugmaker raising the price of a hepatitis C medication by more than 1400%.

Unlock unlimited access to all Global Competition Review content